The Romberg Lab investigates the regulatory mechanisms that enable our immune systems to vigorously attack infectious pathogens but not our own bodies. Particular topics of interest in Dr. Romberg’s lab include the role of T regulatory cells in B cell tolerance, T follicular helper cell dysfunction in common variable immune deficiency-related autoimmune disease, and the role of novel genes and pathways in immunity.
The lab is particularly interested in studying the immune system of patients with primary immunological diseases (PID) who are susceptible to both life-threatening infections and to the development of autoimmune diseases. Greater insights into the pathology of these rare diseases will enable the rationale development of targeted therapies for PIDs and for more common diseases that have an immunologic basis.
In addition to basic scientific work, the Romberg Lab has discovered or has contributed to the discovery of several inherited diseases of the immune system and identified personalized therapies for affected patients. Such disorders include:
- PU.1-mutated agammaglobulinemia (PU.MA)
- CD40LG duplication associated autoimmune disease (40DAD)
- Autoinflammation with infantile enterocolitis (AIFEC)
Dr. Romberg investigates the regulatory mechanisms enabling our immune systems to fight infections without injuring ourselves. He is particularly interested in the immune system of patients with primary immunodeficiency who are susceptible to both life-threatening infections and autoimmune diseases. Greater insights into these rare diseases may enable rationale development of targeted therapies for more common diseases with an immunologic basis.